Progesterone receptors

Ongoing clinical trials and approved products targeting Progesterone receptors, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

3ongoing imaging trials

0approved products

Target note

Full name: Progesterone receptors
Nature: Nuclear receptor whose expression depends on the estrogen pathway.
Normal expression: Uterus.
Value: Early assessment of whether the ER pathway is functional under hormone therapy.
Approaches: [18F]FFNP.
Indications explored: HR+ breast cancer, endometrial cancers (research).
Points of caution: Data still limited.

Ongoing imaging trials · 3Open in the radar →

Trial	Phase	Status	Sponsor	Countries
[18F]FFNPNCT06086704 · Breast	Phase 2	Recruiting	University of Wisconsin, Madison	1
[18F]FFNPNCT05480995 · Gynecological	Phase 2	Active, not recruiting	University of North Carolina, Chapel Hill	1
[18F]FFNPNCT06067503 · Breast	Phase 2	Recruiting	University of Wisconsin, Madison	1

Cite this page

Progesterone receptors. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/progesterone-receptors/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.